About CHROMagar
CHROMagar is a company based in Paris (France) founded in 1979 by Alain Rambach. CHROMagar offers products and services including CHROMagar Serratia, CHROMagar Candida Plus, and CHROMagar B.cepacia. CHROMagar operates in a competitive market with competitors including Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
- Headquarter Paris, France
- Founders Alain Rambach
- SectorsHealthcare
- Website chromagar.com
- Social LinkedIn
Products & Services of CHROMagar
CHROMagar offers a comprehensive portfolio of products and services, including CHROMagar Serratia, CHROMagar Candida Plus, and CHROMagar B.cepacia.
Chromogenic media for detecting Serratia bacteria in diagnostics
Media for identifying Candida species in clinical microbiology
Tools for detecting Burkholderia Cepacia in infection control
People of CHROMagar
1 people are tracked at CHROMagar (1 in leadership).
| Name | Role | Group |
|---|---|---|
Alain Rambach | Founder | Leadership |
Complete people profiles for CHROMagar
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of CHROMagar
CHROMagar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | – | RNA-sequencing transcriptome kits for health data analysis are developed. | |
| biofidelity.com | 2002 | Cambridge, United Kingdom | $59.91M | 28 | Molecular diagnostic assays are developed for target DNA sequence detection. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems | |
| sebia.com | 1967 | Evry Courcouronnes, France | – | – | Electrophoresis-based in vitro diagnostics products are developed and provided. | |
| nuprobe.com | 2016 | George Town, Cayman Islands | $61M | – | Sensitive multiplex platforms for QPCR are developed using toehold probes. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. | |
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing |
Detailed competitors of CHROMagar
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CHROMagar
The website of CHROMagar (chromagar.com) receives about 36.7K visits a month.
- Monthly visits36.7K
▼ 5.6% vs previous month
Websites whose visitors overlap most with CHROMagar. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
medica-tec.com | medica-tec.com | 100% | – | – | – |
ld.ru | ld.ru | 99% | – | #1,234,374 | – |
swacm.org | swacm.org | 89% | – | #8,511,338 | – |
| drg-international.com | 87% | 8.7K | #2,578,154 | View details | |
dehteq.co.za | dehteq.co.za | 55% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for CHROMagar
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to CHROMagar
10 companies that operate in the same segment as CHROMagar (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CHROMagar
CHROMagar was founded in 1979.
CHROMagar is headquartered in Paris, France.
Founded in 1979 in Paris, France, CHROMagar focuses on the production of dehydrated chromogenic culture media within the microbiology sector. These media support the detection and identification of bacterial pathogens in clinical and industrial settings. Operations encompass quality control for food and beverage industries, water analysis, and environmental monitoring. Enumeration of strains like C. perfringens, Enterobacteriaceae, Campylobacter, and Salmonella is facilitated through specialized formulations.
CHROMagar's top competitors include Neogen, Qiagen and Parse Biosciences.
CHROMagar offers CHROMagar Serratia, CHROMagar Candida Plus, and CHROMagar B.cepacia.